

Atty. Docket No. 1311-CON

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

Appl. Serial No.: 10/623,189

Confirmation No.: 3581

SEP 12 2006

Inventors: Alex De Paoli, et al.

TC/A.U.: 1646

Filed: July 18, 2003

Examiner: O'Hara, Eileen B.

**Title:** USE OF LEPTIN FOR TREATING HUMAN  
LIPOATROPHY AND METHOD OF DETERMINING  
PREDISPOSITION TO SAID TREATMENT

FACSIMILE TRANSMITTAL COVER SHEETCertificate of Transmission Under 37 C.F.R. 1.8

I hereby certify that the following listed correspondence in the above-referenced application is being transmitted by facsimile to the Commissioner for Patents, Alexandria, VA to telephone number (571) 273-8300 on this 12th day of September, 2006.



Rachel Potash

Document(s)	No. of Pages
1. Statement Under 37 C.F.R. 3.73(b); Revocation of Previous Power of Attorney and New Power of Attorney By Assignee; Request for Change of Correspondence Address (for Assignee Amgen, Inc.)	2 pages.
2. Statement Under 37 C.F.R. 3.73(b); Revocation of Previous Power of Attorney and New Power of Attorney By Assignee; Request for Change of Correspondence Address (for Assignee The Government of the United States of America as represented by the Secretary, Department of Health and Human Services.)	2 pages; and
3. Statement Under 37 C.F.R. 3.73(b); Revocation of Previous Power of Attorney and New Power of Attorney By Assignee; Request for Change of Correspondence Address (for Assignee The Board of Regents, The University of Texas System)	2 pages.

Total number of pages transmitted (including this page):

7

*NOTE: Each paper must have its own certificate of transmission,  
or this certificate must identify each paper submitted*

Rev. 21-Feb-06

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

SEP 12 2006

Applicants: Alex DePaoli et al.

Docket No.: A-683A

Serial No: 10/623,189

Group Art Unit: 1646

Filed: July 18, 2003

Examiner: O'Hara, Eileen B.

For: USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD  
OF DETERMINING PREDISPOSITION TO SAID TREATMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. 3.73(b)

Amgen Inc. (hereinafter "Amgen"), a corporation of the State of Delaware having a place of business at One Amgen Center Drive, Thousand Oaks, California, 91320, is the joint assignee of the entire right, title, and interest in the above-identified U.S. patent application. Documentary evidence of a chain of title from Alex M. DePaoli to Amgen is demonstrated by:

the assignment recorded in the United States Patent and Trademark Office at Reel 017036, Frame 0640

The undersigned, whose title is supplied below, is empowered to sign this statement on behalf of Amgen.

REVOCATION OF PREVIOUS POWER OF ATTORNEY AND  
NEW POWER OF ATTORNEY BY ASSIGNEE

Amgen hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners named below to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

Name	Registration Number
BUTLER, James E.	40,931
MYERS FITCH, Susan J.	55,477
HILL, Laurie L.	51,804
HOLMAN, Molly A.	40,022
TORCHIA, Timothy E.	36,700
ZACHOW, Karen Rose	46,332
BAROVSKY, Kenneth	36,442

Statement Under 37 C.F.R. 3.73(b) and Power of Attorney by Assignee  
U.S. Patent Application Serial No. 10/623,189

RECEIVED  
CENTRAL FAX CENTER  
SEP 12 2006

REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS

Please send all future correspondence and direct telephone calls to  
Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, California 92121,  
(858) 552-2200.

Respectfully submitted,

Date Aug. 21, 2006

By Stuart L. Watt  
Stuart L. Watt  
Title Vice President, Law

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alex DePaoli et al.

Docket No.: A-683A

RECEIVED  
CENTRAL FAX CENTER  
SEP 12 2006

Serial No: 10/623,189

Group Art Unit: 1646

Filed: July 18, 2003

Examiner: O'Hara, Eileen B.

For: USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD  
OF DETERMINING PREDISPOSITION TO SAID TREATMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. 3.73(b)

The Government of the United States of America as represented by the Secretary, Department of Health and Human Services (hereinafter the "Assignee") is the joint assignee of record of the entire right, title, and interest in the above-identified U.S. patent application, and has a place of business at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804.

Pursuant to 37 C.F.R. 3.73(b), the undersigned has reviewed evidentiary documents establishing a chain of title from inventors to the Assignee and, to the best of the undersigned's knowledge and belief, certifies that title is in the Assignee. The documentary evidence of a chain of title from Simeon I. Taylor and Elif A. Oral to the Assignee is demonstrated by:

the assignment recorded in the United States Patent and Trademark Office at Reel 017036, Frame 0674

REVOCATION OF PREVIOUS POWER OF ATTORNEY AND  
NEW POWER OF ATTORNEY BY ASSIGNEE

The Assignee hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners named below to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

Name	Registration Number
BUTLER, James E.	40,931
MYERS FITCH, Susan J.	55,477
HULL, Laurie L.	51,804
HOLMAN, Molly A.	40,022
TORCHIA, Timothy E.	36,700
ZACHOW, Karen Rose	46,332
BAROVSKY, Kenneth	36,442

Statement Under 37 C.F.R. 3.73(b) and Power of Attorney by Assignee  
U.S. Patent Application Serial No. 10/623,189


RECEIVED  
CENTRAL FAX CENTER

SEP 12 2006

REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS

Please send all future correspondence and direct telephone calls to  
Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, California 92121,  
(858) 552-2200.

Date AUG 30 2006

Signed:   
Name: Norbert Pontzer  
Title: Technology Licensing Specialist  
Address: National Institutes of Health  
6011 Executive Boulevard, Suite 325  
Rockville, MD 20852-3804

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alex DePaoli et al.

Docket No.: A-683A RECEIVED  
CENTRAL FAX CENTER

Serial No: 10/623,189

Group Art Unit: 1646 SEP 12 2006

Filed: July 18, 2003

Examiner: O'Hara, Eilcen B.

For: USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD  
OF DETERMINING PREDISPOSITION TO SAID TREATMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. 3.73(b)

The Board of Regents, The University of Texas System (hereinafter the "Assignee") is the joint assignee of record of the entire right, title, and interest in the above-identified U.S. patent application, and has a place of business at 201 West 7th Street, Austin, Texas 78701-2981.

Pursuant to 37 C.F.R. 3.73(b), the undersigned has reviewed evidentiary documents establishing a chain of title from inventors to the Assignee and, to the best of the undersigned's knowledge and belief, certifies that title is in the Assignee. The documentary evidence of a chain of title from Abhimanyu Garg to the Assignee is demonstrated by:

the assignment recorded in the United States Patent and Trademark Office at Reel 017036,  
Frame 0693

REVOCATION OF PREVIOUS POWER OF ATTORNEY AND  
NEW POWER OF ATTORNEY BY ASSIGNEE

The Assignee hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners named below to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

Name	Registration Number
BUTLER, James E.	40,931
MYERS FITCH, Susan J.	55,477
HILL, Laurie L.	51,804
HOLMAN, Molly A.	40,022
TORCHIA, Timothy E.	36,700
ZACHOW, Karen Rose	46,332
BAROVSKY, Kenneth	36,442

Statement Under 37 C.F.R. 3.73(b) and Power of Attorney by Assignee  
U.S. Patent Application Serial No. 10/623,189

RECEIVED  
CENTRAL FAX CENTER

SEP 12 2006

**REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS**

Please send all future correspondence and direct telephone calls to  
**Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, California 92121,**  
**(858) 552-2200.**

Date 8/28/06

Signed:   
Name: Barry D. Burgeonoff  
Title: Vice Chancellor and General Counsel  
Address: Board of Regents  
The University of Texas System  
201 West 7th Street  
Austin, Texas 78701-2981